ABIOMED

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abiomed (ABMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Abiomed (ABMD) Enters Overbought Territory

Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.

Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function. Annually, more than one milli

Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients

The stock price of Abiomed , a medical devices company best known for Impella, the world's smallest heart pump, looks attractive at current levels of $280, despite it being up 2x from the levels of $132 it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19.

Here's Why Abiomed Stock Is Attractive After A 20% Drop

Despite record revenue for its latest quarter, the medical device maker's shares sank 8% following its earnings release. But its next stage of growth is coming.

Abiomed to Shareholders: Patience Please, Growth Is On The Way.

Align Technology

People will be getting back to their regular routines when it comes to medical and dental care.

The End of the Pandemic Will Mean a Major Boost for These 2 Buy-and-Hold Stalwarts

ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4

Abiomed's (ABMD) CEO Mike Minogue on Q4 2021 Results - Earnings Call Transcript

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $241 million , up 17% year over year, with 26.0% operating margin.

Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin

DANVERS, Mass.--(BUSINESS WIRE)--Dr. Paula Johnson joins the Abiomed Board of Directors

Dr. Paula A. Johnson Joins Abiomed Board of Directors

Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.

ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abiomed (ABMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Abiomed shares continue their positive outlook, driven by sales momentum in the Impella 5.0 & 5.5 platforms. Excellent balance sheet management with no debt load signals, high free cash conversion, and equity concentrated capital structure.

Abiomed: Valuation Drivers Justify The Premium Over Peers

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient was enrolled at Ascension St. John Hospital in Detroit by Dr. Ted Schreiber, chief of cardiology at Asce

First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 29, 2021 the Company will release financial results for the fourth quarter of fiscal 2021.

Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification

STAAR Surgical

Teladoc

I've been waiting to buy these stocks at a better price. Now might just be the time.

Buy These 3 Breakout Healthcare Stocks if There's a Sell-Off or Correction

Guardant Health Inc

Which healthcare company is a better play for the next decade?

Better Buy for the Next 10 Years: Abiomed vs. Guardant Health

There are long-term implications to the coronavirus pandemic that the market is not appreciating.

This Company Will Fix the Hidden COVID Danger to Come

Cantel Medical

CMD vs. ABMD: Which Stock Is the Better Value Option?

CMD or ABMD: Which Is the Better Value Stock Right Now?

This medical device company has revenue growth, patents, and a bright outlook.

Could Abiomed Be a Millionaire-Maker Stock?

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?

Abiomed (ABMD) Down 8.6% Since Last Earnings Report: Can It Rebound?

Deckers Outdoor

Graco

Investors searching for value opportunities may want to have a look at the three stocks listed below, as they represent equities in companies with high profitability and robust financial conditions. In fact, these stocks have GuruFocus profitability and financial strength ratings of at least 7 out of 10.

A Trio of High-Return Businesses with Solid Balance Sheets

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.

Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors

Chipotle

Fortinet

Illumina

MSCI

ResMed

Rollins

Teradyne

Under Armour

Zebra Technologies

The market itself is sitting at lofty valuations, but several S&P 500 stocks are extremely overheated. Consider giving these 10 picks a little time to cool off.

10 S&P 500 Stocks to Consider … At Much Lower Prices

Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.

News for ABIOMED Stock (ABMD)